In December, the Global Fund and the US President’s Emergency Plan for Aids Relief committed to funding the roll-out of lenacapavir in countries they support ...

In December, the Global Fund and the US President’s Emergency Plan for Aids Relief committed to funding the roll-out of ...

As the U.S. market grapples with the impact of newly imposed tariffs and a broad-based sell-off, investors are keenly ...

Gilead Sciences has allocated USD 200 million to potentially settle with federal prosecutors to resolve an investigation into ...

Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...

Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal investigation.

Gutting USAID is already having a devastating impact around the world. In the Democratic Republic of the Congo, teams that ...

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

The FDA has accepted under Priority Review the NDA for lenacapavir for the prevention of HIV as pre-exposure prophylaxis.

A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...